| Author |
Title |
JournalName |
Year D |
| Click on Column Headers to Re-Sort The Current List |
| Samanin R, Mennini T, Fer... |
m-Chlorophenylpiperazine: A Central Serotonin Agonist Causing Powerful... |
Naunyn-Schmiedeberg'... |
1979 |
| Cohen ML, Fuller RW |
Antagonism of vascular serotonin receptors by m-chlorophenylpiperazine... |
Life Sci |
1983 |
| Aloi JA, Insel TR, Muelle... |
Neuroendocrine and Behavioral Effects of m-Chlorophenylpiperazine Admi... |
Life Sciences |
1984 |
| McKenney JD, Glennon RA |
TFMPP May Produce its Stimulus Effects Via a 5-HT1B Mechanism |
Pharmacology Biochem... |
1986 |
| Charney DS, Woods SW, Goo... |
Serotonin function in anxiety II. Effects of the serotonin agonist MCP... |
Psychopharmacology B... |
1987 |
| Aulakh CS, Cohen RM, Hill... |
Long-term imipramine treatment enhances locomotor and food intake supp... |
Br J Pharmacol |
1987 |
| Charney DS, Goodman WK, P... |
Serotonin function in obsessive-compulsive disorder A comparison of th... |
Arch Gen Psychiatry |
1988 |
| Schechter MD |
Use of TFMPP stimulus properties as a model of 5-HT1B receptor activat... |
Pharmacol Biochem Be... |
1988 |
| Klodzinska A, Jaros T, Ch... |
Exploratory hypoactivity induced by m-trifluoromethylphenylpiperazine ... |
J Neural Transm Park... |
1989 |
| Kahn RS, Wetzler S, Asnis... |
Effects of m-chlorophenylpiperazine in normal subjects: a dose-respons... |
Psychopharmacology (... |
1990 |
| Frambes NA, Kirstein CL, ... |
5-HT1A, 5-HT1B and 5-HT2 receptor agonists induce differential behavio... |
Eur J Pharmacol |
1990 |
| Chaouloff F, Laude D, Bau... |
Effects of the 5-HT1C/5-5-HT2 receptor agonists DOI and alpha-methyl-5... |
Eur J Pharmacol |
1990 |
| Boja JW, Schechter MD |
Possible serotonergic and dopaminergic mediation of the N-ethyl-3,4-me... |
Eur J Pharmacol |
1991 |
| Chaouloff F, Baudrie V, L... |
The 5-HT2 receptor agonist 1-2,5-dimethoxy-4-iodophenyl2-aminopropane ... |
Eur J Pharmacol |
1992 |
| Aulakh CS, Hill JL, Yoney... |
Evidence for involvement of 5-HT1C and 5-HT2 receptors in the food int... |
Psychopharmacology (... |
1992 |
| Germine M, Goddard AW, Wo... |
Anger and anxiety responses to m-chlorophenylpiperazine in generalized... |
Biol Psychiatry |
1992 |
| Chaouche-Teyara K, Fourni... |
Vascular and cardiac effects of alpha-methyl-5-HT and DOI are mediated... |
Eur J Pharmacol |
1993 |
| Aulakh CS, Mazzola-Pomiet... |
Evidence that 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane-induced ... |
J Pharmacol Exp Ther |
1994 |
| Benjamin J, Greenberg BD,... |
Daily administration of m-chlorophenylpiperazine to healthy human volu... |
Psychopharmacology B... |
1996 |
| Buydens-Branchey L, Branc... |
Hormonal, psychological, and alcohol craving changes after m-chlorophe... |
Alcohol Clin Exp Res |
1997 |
| Rotzinger S, Fang J, Bake... |
Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from hu... |
Drug Metab Dispos |
1998 |
| McCann UD, Eligulashvili ... |
Altered neuroendocrine and behavioral responses to m-chlorophenylpiper... |
Psychopharmacology (... |
1999 |
| Leone M, Attanasio A, Cro... |
The serotonergic agent m-chlorophenylpiperazine induces migraine attac... |
Neurology |
2000 |
| Baumann MH, Ayestas MA, D... |
1-(m-chlorophenyl)piperazine (mCPP) dissociates in vivo serotonin rele... |
Neuropsychopharmacol... |
2001 |
| Tancer, ME, Johanson, C-E |
The subjective effects of MDMA and mCPP in moderate MDMA users |
Drug and Alcohol Dep... |
2001 |
| Hatzidimitriou G, Tsai EH... |
Altered prolactin response to M-chlorophenylpiperazine in monkeys prev... |
Synapse |
2002 |
| Rothman R, Baumann M |
Therapeutic and adverse actions of serotonin transporter substrates |
Pharmacol Ther |
2002 |
| Gobbi M, Moia M, Pirona L... |
p-Methylthioamphetamine and 1-(m-chlorophenyl)piperazine, two non-neur... |
J Neurochem |
2002 |
| Gijsman HJ, Van Gerven JM... |
Saccadic peak velocity and EEG as end-points for a serotonergic challe... |
Hum Psychopharmacol |
2002 |
| Taffe MA, Davis SA, Yuan ... |
Cognitive performance of MDMA-treated rhesus monkeys: sensitivity to s... |
Neuropsychopharmacol... |
2002 |
| Bull EJ, Hutson PH, Fone ... |
Reduced social interaction following 3,4-methylenedioxymethamphetamine... |
Neuropharmacology |
2003 |
| Peters FT, Schaefer S, St... |
Screening for and validated quantification of amphetamines and of amph... |
J Mass Spectrom |
2003 |
| Taffe MA, Huitron-Resendi... |
MDMA exposure alters cognitive and electrophysiological sensitivity to... |
Pharmacol Biochem Be... |
2003 |
| Tancer M, Johanson CE |
Reinforcing, subjective, and physiological effects of MDMA in humans: ... |
Drug Alcohol Depend |
2003 |
| Maurer HH, Kraemer T, Spr... |
Chemistry, pharmacology, toxicology, and hepatic metabolism of designe... |
Ther Drug Monit |
2004 |
| Feuchtl A, Bagli M, Steph... |
Pharmacokinetics of m-chlorophenylpiperazine after intravenous and ora... |
Pharmacopsychiatry |
2004 |
| Staack RF, Maurer HH |
Metabolism of designer drugs of abuse |
Curr Drug Metab |
2005 |
| Bossong MG, Van Dijk JP, ... |
Methylone and mCPP, two new drugs of abuse? |
Addict Biol |
2005 |
| Johanson CE, Kilbey M, Ga... |
Discriminative stimulus effects of 3,4-methylenedioxymethamphetamine (... |
Drug Alcohol Depend |
2006 |
| Vogels N, Brunt TM, Rigte... |
Content of ecstasy in the Netherlands: 1993-2008 |
Addiction |
2009 |
| Bossong MG, Brunt TM, Van... |
mCPP: an undesired addition to the ecstasy market |
J Psychopharmacol |
2010 |
| Brunt TM, Koeter MW, Nies... |
Linking the pharmacological content of ecstasy tablets to the subjecti... |
Psychopharmacology (... |
2011 |
| Arbo MD, Bastos ML, Carmo... |
Piperazine compounds as drugs of abuse |
Drug Alcohol Depend |
2011 |
| Castelli R2, Thornton SL,... |
True or False? Analysis of phencyclidine positive urine drug immunoass... |
NAACT Abstract |
2015 |
| Adamowicz P, Gieron J, Gi... |
The prevalence of new psychoactive substances in biological material -... |
Drug Test Anal |
2015 |
| Odoardi S, Romolo FS, Str... |
A snapshot on NPS in Italy: Distribution of drugs in seized materials ... |
Forensic Sci Int |
2016 |
